A novel treatment for ovarian cancer (OC): Anti-Mullerian inhibiting substance type II receptor (MISRII) humanized monoclonal antibody (mAb) 3C23K--Preclinical validation.

Christine Gaucher,Alexandra Jacquet,Nathalie Kersual,Véronique Garambois,Alexandre Fontayne,Nathalie Fournier,Christophe de Romeuf,Diego Tosi,A. Sadoun,Frederique Brune,Jean-François Prost,Rémi Urbain,André Pèlegrin,Isabelle Teulon-Navarro

A novel treatment for ovarian cancer (OC): Anti-Mullerian inhibiting substance type II receptor (MISRII) humanized monoclonal antibody (mAb) 3C23K--Preclinical validation.

2012

Christine Gaucher
Alexandra Jacquet
Nathalie Kersual
Véronique Garambois
Alexandre Fontayne
Nathalie Fournier
Christophe de Romeuf
Diego Tosi
A. Sadoun
Frederique Brune
Jean-François Prost
Rémi Urbain
André Pèlegrin
Isabelle Teulon-Navarro

5069 Background: Expressed on most OC subtypes while displaying a restricted expression profile in adult normal tissues, MISRII represents a potentialtarget for OC immunotherapy. We present here th...

Keywords:

Ovarian cancer
Monoclonal antibody
MULLERIAN INHIBITING SUBSTANCE TYPE II RECEPTOR
Cancer research
Immunology
Medicine
Immunotherapy
normal tissue
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations